Epigenetic therapy for cancer

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 3, 2015, Pages 1023-1032

  Saleem, Mohammad ^a   Abbas, Khizar ^a   Manan, Maria ^a   Ijaz, Hira ^a   Ahmed, Bilal ^a   Ali, Muhammad ^b   Hanif, Muhammad ^b   Farooqi, Ammad Ahmad ^c   Qadir, Muhammad Imran ^b  

^a GC UNIVERSITY   (Pakistan)

^b BAHAUDDIN ZAKARIYA UNIVERSITY   (Pakistan)

^c RLMC   (Pakistan)

Author keywords

DNMTs; Epigenetics; HDACs; Silencing

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APICIDIN; AZACITIDINE; BUTYRIC ACID; DACINOSTAT; DECITABINE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; FLUCYTOSINE DEOXYRIBOSIDE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROXAMIC ACID; MG 98; N PHTHALOYLTRYPTOPHAN; NUCLEOSIDE ANALOG; TASIDOTIN; TETRAPEPTIDE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ZEBULARINE; DNA METHYLTRANSFERASE; HISTONE;

CANCER GENE THERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; ENZYME ACTIVE SITE; EPIGENETICS; GENE SEQUENCE; GENE SILENCING; GENOME IMPRINTING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS;

DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; NEOPLASMS;

EID: 84929166501     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Ahmad M, Mahmood Q, Gulzar K, Akhtar MS, Saleem M and Qadir MI (2012). Anti-hyperlipidaemic and hepatoprotective activity of Dodonaea viscosa leaves extracts in alloxan-induced diabetic rabbits (Oryctolagus cuniculus). Pak. Vet. J., 32(1): 50-54.
2. Ameen S, Qadir MI and Ahmad B (2012). Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen. Pak. J. Pharm. Sci., 25(2): 469-476.
3. Amin N, Qadir MI, Khan TJ, Abbas G, Ahmad B, Janbaz KH and Ali M (2012). Antibacterial activity of Vacuum liquid chromatography (VLC) isolated fractions of chloroform extracts of seeds of Achyranthes aspera. J. Chem. Soc. Pak., 34(3): 589-592.
4. Asif MA and Qadir MI (2011). Molecular approaches for development of malarial vaccines. Rev. Pharmacol., 4: 276-278.
5. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L and Versace R et al., (2004). Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVPLAQ824. Cancer Res., 64: 689-695.
6. Bachman KE, Rountree MR and Baylin SB (2001). Dnmt3a and Dnmt3b are transcriptiona repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem., 276: 32282-32287.
7. Barbara KD, Mukesh V and Asad U (2003). Epigenetics in cancer prevention: Early detection and risk assessment. Ann. N.Y. Acad. Sci., 983: 1-4.
8. Baylin SB and Herman JG (2000). DNA hypermethylation in tumor igenesis: Epigenetics joins genetics. Trends Genet, 16: 168-174.
9. Bednarik DP et al (1990). Inactivation of the HIV LTR by DNA CpG methylation: Evidence for a role in latency. EMBO J., 9: 1157-1164.
10. Berger SL et al (2009). An operational definition of epigenetics. Genes Dev., 23: 781.
11. Bestor T, Laudano A and Mattaliano R et al (1988). Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxylterminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J. Mol. Biol., 203: 971-983.
12. Bestor TH (2000). The DNA methyltransferases of mammals. Hum. Mol. Genet, 9: 2395-2402.
13. Beumer JH, Parise RA, Newman EM, Doroshow, JH, Synold TW, Lenz HJ and Egorin MJ (2008). Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother. Pharmacol., 62: 363-368.
14. Billam M, Sobolewski MD and Davidson NE (2010). Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat., 120: 581-592.
15. Bird AP (1986). CpG-rich is lands and the function of DNA methylation. Nature, 321: 2009-2013.
16. Bird AP and Wolffe AP (1999). Methylation-induced repression-Belts. braces and chromatin. Cell, 99: 451-454.
17. Bokhari TH, Hina S, Ahmad M, Iqbal M, Shafiq M, Arshad MN, Asghar MN, Aslam M, Qadir MI (2012). Concentration of 188Re-Perrhenate for Therapeutic Radiopharmaceuticals. J Chem Soc Pak, 35: 147-150.
18. Boothman DA, Briggle TV and Greer S (1989). Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol. Ther., 42: 65-88.
19. Candido EP, Reeves R and Davie JR (1978). Sodium butyrate inhibits histone deacetylation in cultured cells. Cell, 14: 105-113.
20. Chen ZX and Riggs AD (2011). DNA methylation and demethylation in mammals. J. Biol. Chem., 286: 18347-18353.
21. Christman JK (2002). 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene., 21: 5483-5495.
22. Clark SJ and Melki (2002). DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene., 21: 5380-5387.
23. Claus R and Lubbert M (2003). Epigenetic targets in hematopoietic malignancies. Oncogene., 22: 6489-6496.
24. Cortez CC and Jones PA (2008). Chromatin, cancer and drug therapies. Mutat. Res., 647: 44-51.
25. Costello JF and Plass C (2001). Methylation matters. J. Med. Genet, 38: 285-303.
26. Das PM and Singal R (2004). DNA methylation and cancer. J. Clin. Oncol., 22: 4632-4642.
27. Ehrlich M (2002). DNA methylation in cancer: Too much, but also too little. Oncogene., 21: 5400-5413.
28. Ehsan O, Qadir MI, Malik SA, Abbassi WS and Ahmad B (2012). Efficacy of nanogold-insulin as a hypoglycemic agent. J. Chem. Soc. Pak., 34(2): 365-370.
29. Esteller M (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet, 8: 286-298.
30. Fang MH and Ji XM (2009). Histone modification and its application in therapy for hematologic malignancies. Zhongguo Shi. Yan. Xue Ye. Xue Za. Zhi., 17: 816-820.
31. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS (2003). Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 63: 7563-7570.
32. Farooqi AA, Butt G, Yousaf G, Qadir MI, Shaukat U, Mansoor Q, Awan M, Bhatti S, Begum A (2013). Making personalized prostate cancer medicine a reality: Challenges and opportunities in the reestablishment of gold standards. Pak J Pharm Sci, 26: 831-840.
33. Fuks F, Burgers WA and Brehm A et al (2000). DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet, 24: 88-91.
34. Fuks F, Burgers WA and Godin N et al (2001). DNMT3A binds deacetylases and is recruited by a sequencespecific repressor to silence transcription. EMBO J., 20: 2536-2544.
35. Gehring M, Reik W and Henikoff S (2009). DNA demethylation by DNA repair. Trends Genet, 25:82-90.
36. Gowher H and Jeltsch A (2004). Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy. Cancer Biol. Ther., 3: 1062-1068.
37. Hake SB, Xiao A and Allis CD (2004). Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer, 90: 761-769.
38. Handel AE and Ebers GC (2010). Ramagopalan, S.V. Epigenetics: Molecular mechanisms and implications for disease. Trends Mol. Med., 16: 7-16.
39. Hatziapostolou M and Iliopoulos D (2011). Epigenetic aberrations during oncogenesis. Cell. Mol. Life Sci., 68: 1681-1702.
40. Hauschild A et al (2008). Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2- aminophenyl)-carbamoyl]-benzyl}-carbamate inpretreated metastatic melanoma. Melanoma Res., 18: 274-278.
41. Herman JG and Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349: 2042-2054.
42. Hussain A, Khalid SH, Qadir MI, Massud A, Ali M, Khan IU, Saleem M, Iqbal MS, Asghar S and Gul H (2011). Water Uptake and Drug Release Behaviour of Methyl Methacrylate-co-itaconic acid [P(MMA/IA)] Hydrogels Cross-linked with Methylene Bis-acrylamide. J. Drug Delvr. Sci. Tech., 21(3): 249-255.
43. Im JY, Park H, Kang KW, Choi WS and Kim HS (2008). Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem. Biol. Interact, 172: 235-244.
44. Iqbal MZ, Qadir MI, Mallhi TH, Khan YH, Ahmad B (2014). Probiotics and their beneficial effects against various diseases. Pak J Pharm Sci, 27: 405-415.
45. Jain PK (2003). Epigenetics: The role of methylation in the mechanism of action of tumor suppressor genes. Ann. N.Y Acad. Sci., 983: 71-83.
46. Janbaz KH, Jan A, Qadir MI and Gilani AH (2013a). Spasmolytic, bronchodilator and vasorelaxant activity of methanolic extract of Tephrosia purpurea. Acta. Pol. Pharm., 79: 261-269.
47. Janbaz KH, Nizsar U, Ashraf M and Qadir MI (2012). Spasmolytic, bronchodilator and antioxidant activities of Erythrina superosa Roxb. Acta. Pol. Pharm., 69(6): 1111-1117.
48. Janbaz KH, Qadir MI, Jan A and Gilani AH (2013b). Anti-diarrheal activity of methanolic extract of Tephrosia purpurea. Acta. Pol. Pharm., 79: 345-347.
49. Javed F, Qadir MI, Janbaz KH and Ali M (2011). Novel drugs from marine microorganisms. Critical Rev. Micro, 37(3): 245-249.
50. Jones PA and Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat. Rev. Genet, 3: 415-428.
51. Jones PL, Veenstra GJ and Wade PA et al (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Gene., 19: 187-191.
52. Karpf AR and Jones DA (2002). Reactivating the expression of methylation silenced genes in human cancer. Oncogene., 21: 5496-5503.
53. Kass SU, Pruss D and Wolffe AP (1997). How does DNA methylation repress transcription? Trends Genet, 13: 444-449.
54. Khalid SH, Qadir MI, Massud A, Ali M and Rasool MH (2009). Effect of degree of cross-linking on swelling and drug release behaviour of poly(methyl methacrylate-co-itaconic acid) [P(MMA/IA)] hydrogels for site specific drug delivery. J. Drug Delvr. Sci. Tech., 19(6): 413-418.
55. Kim SH, Kang HJ, Na H and Lee MO (2010). Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein. Breast Cancer Res., 12: 22.
56. Kouzarides T (2007). Chromatin modifications and their function. Cell, 128: 693-705.
57. Kristensen LS, Nielsen HM and Hansen LL (2009). Epigenetics and cancer treatment. Eur. J. Pharmacol., 625: 131-142.
58. Kuo HK, Griffith JD and Kreuzer KN (2007). 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res., 67: 8248-8254.
59. Lachner M. et al (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature, 410: 116-120.
60. Mallhi TH, Qadir MI, Khan YH, Ali M (2014). Hepatoprotective activity of aqueous methanolic extract of Morus nigra against paracetamol-induced hepatotoxicity in mice. Bangladesh J Pharmacol, 9: 60-66.
61. Mancini DN, Rodenhiser DI and Ainsworth PJ et al (1998). CpG methylation within the 5= regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene., 16: 1161-1169.
62. Marsoni S, Damia G and Camboni G (2011). A work in progress: The clinical development of histone deacetylase inhibitors. Int. J. Mol. Sci., 12: 4475.
63. Marushige K (1976). Activation of chromatin by acetylation of histone side chains. Proc. Natl. Acad. Sci. USA, 73: 3937-3941.
64. Masood MI, Qadir MI, Shirazi JH and Khan IU (2011). Beneficial effects of lactic acid bacteria on human beings. Critical Rev. Micro, 37(1): 91-98.
65. Mirza S, Sharma G, Pandya P and Ralhan R (2010). Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol. Cell Biochem., 342: 101-109.
66. Moyers SB and Kumar NB (2004). Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials. Nutr. Rev., 62: 204-211.
67. Naz S, Qadir MI, Ali M and Janbaz KH (2012). Nanotechnology for imaging and drug delivery in cancer. J. Chem. Soc. Pak., 34(1): 107-111.
68. Ng HH and Bird A (1999). DNA methylation and chromatin modification. Curr. Opin. Genet Dev., 9: 158-163.
69. Nisa T, Qadir MI and Malik SA (2009). Effect of Eugenia jambolana leaves extracts on blood glucose levels of experimental diabetic rabbits. Pharmacologyonline, 3: 829-835.
70. Panning B and Jaenisch R (1998). RNA and the epigenetic regulation of X chromosome inactivation. Cell, 93: 305-308.
71. Perabo FG and Müller SC (2007). New agents for treatment of advanced transitional cell carcinoma. Annu. Oncol., 18: 835-843.
72. Piña IC, Gautschi JT, Wang GY, Sanders ML Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski, SW and Perez LB et al (2003). Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem., 68: 3866-3873.
73. Qadir MI (2009). Medicinal and cosmetological importance of Aloe vera. Int. J. Nat. Ther., 2: 21-26.
74. Qadir MI (2010) Medicinal values of ginger. Int. J. Nat. Ther., 3: 19-22.
75. Qadir MI (2011) Qadirvirtide. Pak. J. Pharm. Sci., 24(4): 593-595.
76. Qadir MI and Malik SA (2010). Anti-diabetic activity of inorganic metals Eugenia jambolana Lam. (Myrtaceae) flowers. Pharmacologyonline, 2: 979-985.
77. Qadir MI, Ahmad B, Ali M, Saleem M, Ali M (2013). Natural hepatoprotectives: Natural medicines for hepatitis. RGUHS J Pharm Sci, 3: 26-34.
78. Qadir MI, Ali M, Ali M, Saleem M, Hanif M (2014b). Hepatoprotective activity of aqueous methanolic extract of Viola odorata against paracetamol-induced liver injury in mice. Bangladesh J Pharmacol, 9: 198-202.
79. Qadir MI, Murad MSA, Ali M, Saleem M, Farooqi AA (2014a). Hepatoprotective effect of leaves of aqueous ethanol extract of Cestrum nocturnum against paracetamol-induced hepatotoxicity. Bangladesh J Pharmacol, 9: 167-170.
80. Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L and Berg SL (2000). Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (Nacetyldinaline) in the nonhuman primate. Clin. Cancer Res., 6: 994-997.
81. Robertson AB, Dahl JA, Vågbø CB, Tripathi P, Krokan HE and Klungland A (2011). A novel method for the efficient and selective identification of 5- hydroxymethylcytosine in genomic DNA. Nucleic Acids Res., 39: 55.
82. Robertson KD, Ait-Si-Ali S and Yokochi T et al (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2Fresponsive promoters. Nat. Genet, 25: 338-342.
83. Rountree MR, Bachman KE and Baylin SB (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet, 25: 269-277.
84. Saleem M, Ahmed B, Qadir MI, Mahrukh, Rafiq M, Ahmad M, Ahmad B (2014a). Hepatoprotective effect of Chenopodium murale in mice. Bangladesh J Pharmacol, 9: 124-128.
85. Saleem M, Karim M, Qadir MI, Ahmad B, Rafiq M, Ahmad B (2014b). In vitro antibacterial activity and phytochemical analysis of hexane extract of Vicia sativa. Bangladesh J Pharmacol, 9: 189-193.
86. Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Irshad T, Ahmad B (2013). Inhibitors of apoptotic proteins: New targets for anti-cancer therapy. Chem Biol Dru Desi, 82: 243-251.
87. Schaefer M, Hagemann S, Hanna K and Lyko F (2009). Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res., 69: 8127-8132.
88. Shi Y et al (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119: 941-953.
89. Srivastava RK, Kurzrock R and Shankar S (2010). MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis and reverses epithelial-mesenchymal transition in vivo. Mol. Cancer Ther., 9: 3254-3266.
90. Stearns V, Zhou Q and Davidson NE (2007). Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest, 25: 659-665.
91. Suzuki H, Gabrielson E and Chen W et al (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet, 31: 141-149.
92. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala, H, Brudno Y, Agarwal S, Iyer LM, Liu DR and Aravind L et al (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324: 930-935.
93. Tate PH and Bird AP (1993). Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet Dev., 3: 226-231.
94. Van Holde KE (1988). Chromatin: Springer series in molecular Biology, Springer-Verlag, New York, pp.15-34.
95. Voso MT, D'Alò F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, Fianchi L, Guidi F and Hohaus S et al (2010). Epigenetic changes in therapy-related MDS/AML. Chem. Biol. Interact, 184: 46-49.
96. rd ed., Academic, San Diego, pp.56.
97. Xu WS, Perez G, Ngo L and Gui CY (2005). Marks, P.A. Induction of polyploidy by histone deacetylase inhibitor: A pathway for anti-tumor effects. Cancer Res., 65: 7832-7839.